Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections
Public ClinicalTrials.gov record NCT05138822. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Double Dummy, Randomized, Phase 1b, Nitrofurantoin Controlled, Repeat Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Microbiological Response of GSK3882347 in Female Participants With Acute Uncomplicated Urinary Tract Infection
Study identification
- NCT ID
- NCT05138822
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 140 participants
Conditions and interventions
Interventions
- GSK3882347 Drug
- Nitrofurantoin Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 17, 2022
- Primary completion
- Dec 2, 2024
- Completion
- Dec 2, 2024
- Last update posted
- Mar 12, 2026
2022 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Lomita | California | 90717 | — |
| GSK Investigational Site | Modesto | California | 95350-5365 | — |
| GSK Investigational Site | Doral | Florida | 33166 | — |
| GSK Investigational Site | Miami | Florida | 33186 | — |
| GSK Investigational Site | Miami Lakes | Florida | 33016-1507 | — |
| GSK Investigational Site | Palmetto Bay | Florida | 33157 | — |
| GSK Investigational Site | Sweetwater | Florida | 33172 | — |
| GSK Investigational Site | Chicago | Illinois | 60643 | — |
| GSK Investigational Site | The Bronx | New York | 10456 | — |
| GSK Investigational Site | Smithfield | Pennsylvania | 15478 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Houston | Texas | 77061 | — |
| GSK Investigational Site | Missouri City | Texas | 77459 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05138822, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05138822 live on ClinicalTrials.gov.